Market capitalization | $17.45m |
Enterprise Value | $30.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.23 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-19.69m |
Free Cash Flow (TTM) Free Cash Flow | $-18.04m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Finch Therapeutics Group Inc:
1 Analyst has issued a forecast Finch Therapeutics Group Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.18 -0.18 |
95%
95%
|
|
EBITDA | -20 -20 |
73%
73%
|
EBIT (Operating Income) EBIT | -20 -20 |
74%
74%
|
Net Profit | -14 -14 |
90%
90%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.
Head office | United States |
CEO | Matthew Blischak |
Employees | 1 |
Founded | 2014 |
Website | www.finchtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.